Abstract 2785
Background
In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo and was associated with reductions in tumour burden in pts with measurable disease (Coleman et al. Lancet. 2017;390:1949-61). This exploratory analysis evaluated the efficacy of rucaparib in ARIEL3 pts based on their best response to last platinum-based chemotherapy prior to enrolment.
Methods
Pts were randomised 2:1 to oral rucaparib (600 mg BID) or placebo. Subgroup analysis was based on a randomisation stratification factor of best response to last platinum-based chemotherapy: complete response (CR) or partial response (PR). PFS was assessed in 3 predefined nested cohorts: BRCA mutant, BRCA mutant + BRCA wild type/high loss of heterozygosity (LOH), and the intent-to-treat (ITT) population. Response was also assessed for pts with nonmeasurable disease (eg, lesions <10 mm) at baseline. For PFS and response, tumours were assessed per RECIST v1.1.
Results
The visit cutoff dates for efficacy and safety were 15 Apr 2017 and 31 Dec 2017. Rucaparib significantly improved PFS vs placebo in the CR and PR subgroups, with a similar treatment effect in both subgroups across all cohorts (Table). Of pts with nonmeasurable disease at baseline, 23/104 (22.1%) rucaparib pts and 2/56 (3.6%) placebo pts had a CR, including 7 rucaparib pts without a BRCA mutation or high LOH. The most common grade ≥3 treatment-emergent adverse event (rucaparib vs placebo) was anaemia/decreased haemoglobin (CR subgroup, 24.0% vs 0%; PR subgroup, 20.2% vs 0.8%).Table: 1001P
Cohort | Rucaparib, n | Placebo, n | Investigator-assessed PFS (primary endpoint) | BICR-assessed PFS (secondary endpoint) | ||
---|---|---|---|---|---|---|
Median PFS, mo; rucaparib vs placebo; P valuea | HR (95% CI) | Median PFS, mo; rucaparib vs placebo; P valuea | HR (95% CI) | |||
CR to last platinum-based chemotherapy | ||||||
BRCA mutant | 43 | 22 | 22.9 vs 7.4; P < 0.0001 | 0.30 (0.15–0.58) | NR vs 7.4; P < 0.0001 | 0.21 (0.09–0.49) |
BRCA mutant or BRCA wild type/high LOH | 82 | 41 | 13.9 vs 7.3; P < 0.0001 | 0.37 (0.23–0.60) | 24.7 vs 7.4; P < 0.0001 | 0.36 (0.21–0.64) |
ITT | 126 | 64 | 11.1 vs 5.6; P < 0.0001 | 0.33 (0.23–0.49) | 19.2 vs 5.5; P < 0.0001 | 0.34 (0.22–0.51) |
PR to last platinum-based chemotherapy | ||||||
BRCA mutant | 87 | 44 | 15.7 vs 4.9; P < 0.0001 | 0.20 (0.13–0.33) | 26.8 vs 4.9; P < 0.0001 | 0.20 (0.11–0.35) |
BRCA mutant or BRCA wild type/high LOH | 154 | 77 | 13.1 vs 4.9; P < 0.0001 | 0.29 (0.21–0.41) | 19.5 vs 4.7; P < 0.0001 | 0.32 (0.21–0.48) |
ITT | 249 | 125 | 9.0 vs 5.3; P < 0.0001 | 0.38 (0.30–0.49) | 13.6 vs 5.3; P < 0.0001 | 0.36 (0.27–0.49) |
HRs estimated with a Cox proportional hazards model. P values were nonsignificant for the treatment by best response subgroup (CR vs PR) interaction tests for investigator-assessed PFS (BRCA-mutant cohort, P = 0.5680; BRCA-mutant + BRCA wild-type/high LOH cohort, P = 0.4092; ITT population, P = 0.7001) and BICR-assessed PFS (BRCA-mutant cohort, P = 0.9192; BRCA-mutant + BRCA wild-type/high LOH cohort, P = 0.8383; ITT population, P = 0.7976). aStratified log-rank P value. BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; NR, not reached.
Conclusions
Regardless of response to last platinum-based chemotherapy, rucaparib maintenance treatment significantly improved PFS vs placebo across all cohorts. Similar to pts with measurable disease at baseline, CRs were observed in rucaparib-treated pts with nonmeasurable disease. Safety was consistent across the CR and PR subgroups.
Clinical trial identification
NCT01968213.
Editorial acknowledgement
Nathan Yardley, PhD, and Shannon Davis of Ashfield Healthcare Communications (Middletown, CT, USA), funded by Clovis Oncology, Inc. (Boulder, CO, USA).
Legal entity responsible for the study
Clovis Oncology, Inc.
Funding
Clovis Oncology, Inc.
Disclosure
J.A. Ledermann: Honoraria (self), Advisory / Consultancy: Clovis Oncology, Inc.; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy: Pfizer; Advisory / Consultancy: Artios Pharma; Advisory / Consultancy: Cristal Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): Merck/Merck Sharp & Dohme; Advisory / Consultancy: Regeneron; Advisory / Consultancy: Roche; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Tesaro. A.M. Oza: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy: Amgen; Advisory / Consultancy: Immunovaccine; Advisory / Consultancy: Verastem; Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self): WebRx. D. Lorusso: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: ImmunoGen; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Takeda; Advisory / Consultancy: Tesaro. C. Aghajanian: Honoraria (self), Advisory / Consultancy, Non-remunerated activity/ies: Clovis Oncology, Inc.; Honoraria (self), Non-remunerated activity/ies: Mateon Therapeutics; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Cerulean Pharma; Honoraria (self), Advisory / Consultancy: Tesaro; Honoraria (self), Advisory / Consultancy: VentiRx. A. Oaknin: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: ImmunoGen; Advisory / Consultancy: Genmab/Seattle Genetics; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro. A. Dean: Advisory / Consultancy: Precision Oncology Australia; Advisory / Consultancy: Shire Pharmaceuticals; Advisory / Consultancy: Specialised Therapeutics Australia. N. Colombo: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy: Advaxis; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BIOCAD; Advisory / Consultancy: Pfizer; Advisory / Consultancy: PharmaMar; Advisory / Consultancy: Roche; Advisory / Consultancy: Tesaro. J.I. Weberpals: Research grant / Funding (institution): AbbVie; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca. A.R. Clamp: Travel / Accommodation / Expenses: Clovis Oncology, Inc.; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Roche. G. Scambia: Advisory / Consultancy: Clovis Oncology, Inc.; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: PharmaMar; Advisory / Consultancy: Roche; Advisory / Consultancy: Tesaro. A. Leary: Advisory / Consultancy: Clovis Oncology, Inc.; Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Pfizer; Advisory / Consultancy: PharmaMar; Research grant / Funding (institution): GamaMabs; Research grant / Funding (institution): Merus. R.W. Holloway: Advisory / Consultancy, Speaker Bureau / Expert testimony: Clovis Oncology, Inc.; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Tesaro. M. Amenedo Gancedo: Speaker Bureau / Expert testimony: Clovis Oncology, Inc.; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: PharmaMar; Speaker Bureau / Expert testimony: Roche. P.C. Fong: Advisory / Consultancy: Clovis Oncology, Inc.; Honoraria (self), Advisory / Consultancy: AstraZeneca. J.C. Goh: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: Janssen; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Travel / Accommodation / Expenses: Astellas Pharma, Inc. D.M. O’Malley: Advisory / Consultancy, Research grant / Funding (institution), Non-remunerated activity/ies: Clovis Oncology, Inc.; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Gynecologic Oncology Group; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy: Myriad; Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Non-remunerated activity/ies: Amgen; Research grant / Funding (institution), Non-remunerated activity/ies: ImmunoGen; Advisory / Consultancy: AbbVie; Advisory / Consultancy: Ambry; Advisory / Consultancy: Health Analytics; Research grant / Funding (institution): Agenus; Research grant / Funding (institution): Ajinomoto; Research grant / Funding (institution): Array BioPharma; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): ERGOMED Clinical Research; Research grant / Funding (institution): Exelixis; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): INC Research. T. Cameron: Shareholder / Stockholder / Stock options, Employee: Clovis Oncology, Inc. L. Maloney: Shareholder / Stockholder / Stock options, Employee: Clovis Oncology, Inc. S. Goble: Shareholder / Stockholder / Stock options, Employee: Clovis Oncology, Inc. R.L. Coleman: Advisory / Consultancy, Research grant / Funding (institution): Clovis Oncology, Inc.; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Bayer; Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory / Consultancy, Research grant / Funding (institution): Esperance; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Millennium; Advisory / Consultancy, Research grant / Funding (institution): OncoMed; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): GamaMabs; Research grant / Funding (institution): Genmab; Research grant / Funding (institution): Gradalis.
Resources from the same session
5124 - STAR_PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer.
Presenter: Hemant Kocher
Session: Poster Display session 2
Resources:
Abstract
5257 - Outcomes of First Line FOLFIRINOX (FFX) Versus Gemcitabine and Nab-Paclitaxel (GN) in Patients with Advanced Pancreatic Cancer: Multi-Institutional Canadian Sites Experience
Presenter: Neha Papneja
Session: Poster Display session 2
Resources:
Abstract
1166 - Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma
Presenter: Chaobin He
Session: Poster Display session 2
Resources:
Abstract
1169 - Association of combination of irreversible electroporation ablation and chemotherapy with outcomes of locally advanced pancreatic cancer: a large cohort study
Presenter: Chaobin He
Session: Poster Display session 2
Resources:
Abstract
1222 - Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer
Presenter: Yusuke Hashimoto
Session: Poster Display session 2
Resources:
Abstract
1698 - Multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer
Presenter: Masato Ozaka
Session: Poster Display session 2
Resources:
Abstract
2424 - Irinotecan Combined with Oxaliplatin and S1 in Patients with Metastatic Pancreatic Adenocarcinoma
Presenter: Keke Nie
Session: Poster Display session 2
Resources:
Abstract
2885 - Cancer-associated thrombosis in patients with pancreatic cancer and its correlation with plasma tissue factor level: A Japanese prospective cohort study
Presenter: Satoshi Kobayashi
Session: Poster Display session 2
Resources:
Abstract
3702 - A Phase I/Ib, multi-center trial of ARQ-761 (Beta-Lapachone) with gemcitabine/nab-Paclitaxel in patients with advanced pancreatic cancer
Presenter: Muhammad Beg
Session: Poster Display session 2
Resources:
Abstract
5185 - Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial
Presenter: Rocio Garcia-Carbonero
Session: Poster Display session 2
Resources:
Abstract